Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

53 comunicati stampa

Guarda tutti i comunicati
30/05/2025
Farmaceutica
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
30/05/2025
Farmaceutica
Medicina Salute Benessere
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
29/05/2025
Farmaceutica
Medicina Salute Benessere
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmaceutica
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmaceutica
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
27/05/2025
Farmaceutica
Medicina Salute Benessere
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
22/05/2025
Farmaceutica
Finanza
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
20/05/2025
Farmaceutica
Finanza
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
20/05/2025
Farmaceutica
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0
19/05/2025
Farmaceutica
Finanza
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0